Hypoglycemia in infants and children can have potentially devastating consequences if not properly managed. It is defined as a blood glucose level below 55 mg/dL. The brain relies heavily on glucose for energy in early life. Persistent hypoglycemia can impair brain growth and development. Causes include decreased glucose production, increased glucose utilization, infections, metabolic disorders, and others. Symptoms range from autonomic activation to neurological changes like seizures. Management involves identifying the cause, treating any underlying condition, monitoring blood glucose closely, and administering intravenous glucose to prevent hypoglycemia.
This document discusses neonatal hypoglycemia and hyperglycemia. It begins by explaining the physiology of glucose homeostasis in newborns, including their dependence on maternal glucose prenatally and the body's response to low blood sugar through gluconeogenesis and ketone production. It then defines hypoglycemia, discusses its incidence in high-risk newborns, and identifies potential etiologies like hyperinsulinism. Clinical features and diagnostic methods are outlined, along with treatment approaches focused on early feeding and prevention in at-risk infants.
Neonatal hypoglycemia and hyperglycemia Dr vijitha ASVijitha A S
油
Neonatal hypoglycemia and hyperglycemia BY Dr VIJITHA A S
Hypoglycemia is most common metabolic problem seen in newborns
No universally accepted definition ; Hypoglycemia cut off variable
pediatrics emergency, hypoglycemia of infancy.
Glucose level can drop if:
There is too much insulin in the blood (hyperinsulinism). Insulin is a hormone that pulls glucose from the blood.
The baby is not producing enough glucose.
The baby's body is using more glucose than is being produced.
The baby is not able to feed enough to keep glucose level up.
This document discusses the approach to hypoglycemia in childhood. It begins by defining hypoglycemia and describing the importance of glucose for brain development. It then discusses the pathophysiology of hypoglycemia, focusing on how the body maintains blood glucose levels through glycogenolysis, gluconeogenesis, and lipolysis. The clinical features of hypoglycemia are presented, distinguishing between sympathetic overactivity and neuroglycopenic symptoms. Common etiologies like hyperinsulinism, metabolic disorders, and systemic illnesses are outlined. The document concludes with recommendations for investigating hypoglycemia, managing acute episodes, and treating underlying causes to prevent long-term neurological consequences.
This document discusses the approach to hypoglycemia in childhood. It begins by defining hypoglycemia and describing the importance of glucose for brain development. It then discusses the pathophysiology of hypoglycemia, focusing on how the body maintains blood glucose levels through glycogenolysis, gluconeogenesis, and lipolysis. The clinical features of hypoglycemia are presented, distinguishing between sympathetic overactivity and neuroglycopenic symptoms. Common etiologies like hyperinsulinism, metabolic disorders, and systemic illnesses are outlined. The document concludes with recommendations for investigating hypoglycemia, managing acute episodes, and treating underlying causes to prevent long-term neurological consequences.
Some additional things to ask in the history:
- Family history of similar episodes or endocrine disorders
- Dietary history, including any changes in appetite/food intake
- Growth pattern and any slowing of growth
- Pubertal development
Some additional things to examine:
- Vital signs - check for signs of dehydration, shock
- Detailed physical exam looking for signs of other endocrine abnormalities
- Developmental assessment
- Nutritional status
Investigations to consider:
- Electrolytes, liver/renal function tests
- Cortisol, ACTH to check for primary adrenal insufficiency
- Thyroid function tests
- Growth hormone stimulation test
- Blood glucose curve/
Neonatal hypoglycemia occurs when blood glucose levels drop dangerously low in newborns. It affects 5-15% of infants and can cause neurological damage if untreated. The document discusses the causes, signs, classifications, diagnosis, treatment and prevention of neonatal hypoglycemia. It emphasizes the importance of monitoring blood glucose levels in at-risk infants, providing IV dextrose or feeding to raise glucose, and supporting breastfeeding to help prevent hypoglycemia. Nursing care focuses on stabilizing blood glucose through nutrition and medical management.
The document discusses neonatal hypoglycemia, including:
1. Hypoglycemia is common in newborns, especially sick ones, as they transition from receiving glucose from the placenta.
2. The brain relies heavily on steady glucose, so low blood sugar can impact brain development if not addressed.
3. At-risk newborns include preterms, SGA, LGA, those with infections or perinatal stressors.
4. Treatment involves monitoring blood sugar based on risk level and intervening with oral or IV glucose if levels dip below thresholds.
This document discusses neonatal hypoglycemia in a newborn baby referred from another hospital. It provides details on the baby's condition, history, treatment and monitoring. It also includes an overview of neonatal glucose homeostasis, the definition of hypoglycemia, classification of neonatal hypoglycemia, special considerations for preterm infants, SGA infants and infants of diabetic mothers. It outlines who should be screened for hypoglycemia and the recommended frequency of blood glucose monitoring based on risk factors.
This document discusses neonatal hypoglycemia. It begins by explaining glucose physiology in fetuses and the adaptations required at birth. It then defines neonatal hypoglycemia and discusses the various etiologies including endocrine disorders, decreased substrate availability, and increased glucose utilization. Symptoms, screening, and management including prevention, treatment with oral feeds or IV therapy, and treatment of persistent or severe hypoglycemia are covered. The importance of aggressively managing hypoglycemia to prevent neurological damage is emphasized.
Neonatal hypocalcemia can present with jitteriness, seizures, and other neurological symptoms. It is commonly seen in preterm infants, infants of diabetic mothers, and those with perinatal asphyxia or maternal conditions affecting calcium homeostasis. Diagnosis is made via serum calcium and magnesium levels. Treatment involves calcium gluconate administered intravenously or orally as well as magnesium supplementation if hypomagnesemia is also present. Close monitoring is needed given risks of complications. Late onset hypocalcemia may require increased oral calcium intake and reduced phosphate intake.
The document outlines congenital hyperinsulinism, which is characterized by inappropriate insulin secretion causing hypoglycemia. It discusses the pathophysiology, causes, diagnosis, and treatment of congenital hyperinsulinism, including medications like diazoxide and octreotide as well as potential surgical interventions. The management of congenital hyperinsulinism is crucial to prevent neurodevelopmental issues associated with prolonged hypoglycemia.
Approach to Hypoglycemia in Children.pptxJwan AlSofi
油
Introduction
DEFINITION
Symptoms and Signs of Hypoglycemia
Sequelae of Hypoglycemia
Hormonal Signal
Regulation of serum glucose
Disorders of Hypoglycemia
Classification of Hypoglycemia in Infants and Children
DIAGNOSIS
EMERGENCY MANAGEMENT
1) Infants of diabetic mothers (IDM) are at risk for complications during pregnancy and birth due to maternal hyperglycemia and the fetus's resulting hyperinsulinemia. Complications for the fetus include increased birth weight, hypoglycemia, hypocalcemia, and respiratory distress.
2) The Pederson hypothesis explains that maternal hyperglycemia causes fetal hyperglycemia and hyperinsulinemia after 20 weeks of gestation as the fetal pancreas matures. This excess insulin promotes increased growth in the fetus.
3) Management of IDM focuses on stabilizing blood glucose with IV dextrose supplementation and feeding support, and treating electrolyte abnormalities like hypocalcemia and hypomagnesemia
Persistent hypoglycemia in newborns can be caused by hyperinsulinemia. There are different types including transient, prolonged, and congenital hyperinsulinemic hypoglycemia. Congenital hyperinsulinemia is often due to genetic defects affecting insulin secretion and can lead to permanent brain injury if not treated aggressively. Initial treatment involves maintaining blood glucose levels through increased carbohydrate intake and intravenous glucose. Medications like diazoxide and octreotide aim to reduce insulin secretion. For resistant cases, genetic testing and imaging can help determine if surgery is required to remove part of the pancreas producing excess insulin. Early diagnosis and management are important to prevent hypoglycemia-induced brain damage in newborns.
Transient Neonatal Hypoglycemia, Revisited discusses glucose homeostasis in neonates and the types and management of neonatal hypoglycemia. After birth, neonates undergo a physiological transition as they adapt to intermittent feeding from transplacental glucose supply. This involves endocrine changes and the activation of pathways like glycogenolysis and gluconeogenesis to maintain blood glucose levels. Insulin secretion in neonates is not suppressed until very low glucose levels due to a lower threshold for insulin release that helps support growth in fetal life. Exposure to hypoxia after birth can prolong this fetal pattern of insulin secretion. Careful management is needed to avoid overtreatment of transitional hypoglycemia while preventing brain injury from severe hypoglycemia.
This document discusses neonatal hypoglycemia and glucose homeostasis in newborns. It begins by outlining glucose regulation in fetal life and the physiological transition that occurs after birth as the newborn adapts from receiving continuous glucose from the placenta to intermittent feeding. This transition involves endocrine changes including a fall in insulin and a rise in stress hormones that stimulate gluconeogenesis and glycogenolysis. The document then discusses the lower glucose threshold for insulin secretion in newborns compared to older infants, which can lead to transient hypoglycemia. It reviews studies showing normal glucose and ketone levels over the first days of life and defines thresholds for hypoglycemia.
The document discusses the management of neonatal hypoglycemia. It defines hypoglycemia and lists its common causes such as excess insulin, limited glycogen storage, and decreased gluconeogenesis. It classifies hypoglycemia as transient or persistent and describes the management and treatment approaches for each type. Nursing management plays an important role in prevention, maintaining normal blood glucose levels, and treating hypoglycemic events. Untreated hypoglycemia can lead to serious complications affecting the brain and heart.
Hypoglycaemia Biochemistry decrease in Glucose mechanismMirzaNaadir
油
glucose decrease due to lots of reason because there are lots of problem regerding it i detail i have given its problems and causes and symptoms and treatment also
Neonatal Hypoglycemia approach and Management .pptxAzad Haleem
油
Dr. Azad Haleem provides an overview of neonatal hypoglycemia. Key points include:
1) Neonates are susceptible to hypoglycemia due to their high brain glucose needs and immature defenses against low blood sugar. Transitional hypoglycemia is common in the first 48 hours while persistent low blood sugar beyond 48 hours requires investigation.
2) Causes of persistent hypoglycemia include hyperinsulinism, hypopituitarism, inborn errors of metabolism, and rarely other conditions. Diagnostic testing aims to identify the underlying etiology.
3) Management involves glucose supplementation, identifying and treating the cause, and careful feeding advancement. Specific treatments depend on the condition, such as diet modifications for
This document discusses neonatal hypoglycemia, including its definition, causes, signs and symptoms, and treatment. It defines neonatal hypoglycemia as a plasma glucose level below 40 mg/dL. Causes include increased glucose utilization, decreased substrate availability, or both. Signs are non-specific and include jitteriness, apnea, and seizures. Treatment involves oral feeds, IV dextrose if needed, and medications like hydrocortisone or diazoxide for persistent hypoglycemia. Close monitoring of at-risk infants is important to prevent neurological damage from prolonged hypoglycemia.
1) Hypoglycemia is common in newborns, affecting 1-3 per 1000 live births, with risk decreasing with increasing gestational age.
2) Significant neurodevelopmental deficits can occur in neonates who experience prolonged hypoglycemia. Studies in monkeys and infants show neuronal injury, particularly in parieto-occipital cortex and other regions.
3) There is no consensus on the definition and threshold for treating hypoglycemia. Guidelines generally recommend treating if blood glucose is less than 50 mg/dL in symptomatic newborns or less than 36 mg/dL in at-risk but asymptomatic newborns.
This document provides information on neonatal hyperbilirubinemia or jaundice. It defines jaundice and discusses the mechanisms and risk factors for both physiologic and pathologic hyperbilirubinemia in newborns. It outlines the evaluation, management, and treatment of hyperbilirubinemia including phototherapy and exchange transfusion. The major points covered are the definition of jaundice, causes of increased and decreased bilirubin levels in newborns, clinical assessment and lab evaluation of hyperbilirubinemia, guidelines for phototherapy and exchange transfusion, and methods to optimize phototherapy treatment.
This document discusses neonatal jaundice and hyperbilirubinemia. It begins by defining jaundice and hyperbilirubinemia. It then describes the metabolism of bilirubin, including transport to the liver, hepatic uptake, conjugation in the liver, and excretion in bile and stool. Causes of increased bilirubin production are discussed, including increased red blood cell production or breakdown. The document also discusses approaches to evaluating and managing neonatal jaundice and hyperbilirubinemia, including assessing risk factors, monitoring bilirubin levels, and guidelines for initiating phototherapy.
Blind Spots in AI and Formulation Science Knowledge Pyramid (Updated Perspect...Ajaz Hussain
油
This presentation delves into the systemic blind spots within pharmaceutical science and regulatory systems, emphasizing the significance of "inactive ingredients" and their influence on therapeutic equivalence. These blind spots, indicative of normalized systemic failures, go beyond mere chance occurrences and are ingrained deeply enough to compromise decision-making processes and erode trust.
Historical instances like the 1938 FD&C Act and the Generic Drug Scandals underscore how crisis-triggered reforms often fail to address the fundamental issues, perpetuating inefficiencies and hazards.
The narrative advocates a shift from reactive crisis management to proactive, adaptable systems prioritizing continuous enhancement. Key hurdles involve challenging outdated assumptions regarding bioavailability, inadequately funded research ventures, and the impact of vague language in regulatory frameworks.
The rise of large language models (LLMs) presents promising solutions, albeit with accompanying risks necessitating thorough validation and seamless integration.
Tackling these blind spots demands a holistic approach, embracing adaptive learning and a steadfast commitment to self-improvement. By nurturing curiosity, refining regulatory terminology, and judiciously harnessing new technologies, the pharmaceutical sector can progress towards better public health service delivery and ensure the safety, efficacy, and real-world impact of drug products.
More Related Content
Similar to MANAGEMENT AND APPROACH OF (3).pptx (20)
The document discusses neonatal hypoglycemia, including:
1. Hypoglycemia is common in newborns, especially sick ones, as they transition from receiving glucose from the placenta.
2. The brain relies heavily on steady glucose, so low blood sugar can impact brain development if not addressed.
3. At-risk newborns include preterms, SGA, LGA, those with infections or perinatal stressors.
4. Treatment involves monitoring blood sugar based on risk level and intervening with oral or IV glucose if levels dip below thresholds.
This document discusses neonatal hypoglycemia in a newborn baby referred from another hospital. It provides details on the baby's condition, history, treatment and monitoring. It also includes an overview of neonatal glucose homeostasis, the definition of hypoglycemia, classification of neonatal hypoglycemia, special considerations for preterm infants, SGA infants and infants of diabetic mothers. It outlines who should be screened for hypoglycemia and the recommended frequency of blood glucose monitoring based on risk factors.
This document discusses neonatal hypoglycemia. It begins by explaining glucose physiology in fetuses and the adaptations required at birth. It then defines neonatal hypoglycemia and discusses the various etiologies including endocrine disorders, decreased substrate availability, and increased glucose utilization. Symptoms, screening, and management including prevention, treatment with oral feeds or IV therapy, and treatment of persistent or severe hypoglycemia are covered. The importance of aggressively managing hypoglycemia to prevent neurological damage is emphasized.
Neonatal hypocalcemia can present with jitteriness, seizures, and other neurological symptoms. It is commonly seen in preterm infants, infants of diabetic mothers, and those with perinatal asphyxia or maternal conditions affecting calcium homeostasis. Diagnosis is made via serum calcium and magnesium levels. Treatment involves calcium gluconate administered intravenously or orally as well as magnesium supplementation if hypomagnesemia is also present. Close monitoring is needed given risks of complications. Late onset hypocalcemia may require increased oral calcium intake and reduced phosphate intake.
The document outlines congenital hyperinsulinism, which is characterized by inappropriate insulin secretion causing hypoglycemia. It discusses the pathophysiology, causes, diagnosis, and treatment of congenital hyperinsulinism, including medications like diazoxide and octreotide as well as potential surgical interventions. The management of congenital hyperinsulinism is crucial to prevent neurodevelopmental issues associated with prolonged hypoglycemia.
Approach to Hypoglycemia in Children.pptxJwan AlSofi
油
Introduction
DEFINITION
Symptoms and Signs of Hypoglycemia
Sequelae of Hypoglycemia
Hormonal Signal
Regulation of serum glucose
Disorders of Hypoglycemia
Classification of Hypoglycemia in Infants and Children
DIAGNOSIS
EMERGENCY MANAGEMENT
1) Infants of diabetic mothers (IDM) are at risk for complications during pregnancy and birth due to maternal hyperglycemia and the fetus's resulting hyperinsulinemia. Complications for the fetus include increased birth weight, hypoglycemia, hypocalcemia, and respiratory distress.
2) The Pederson hypothesis explains that maternal hyperglycemia causes fetal hyperglycemia and hyperinsulinemia after 20 weeks of gestation as the fetal pancreas matures. This excess insulin promotes increased growth in the fetus.
3) Management of IDM focuses on stabilizing blood glucose with IV dextrose supplementation and feeding support, and treating electrolyte abnormalities like hypocalcemia and hypomagnesemia
Persistent hypoglycemia in newborns can be caused by hyperinsulinemia. There are different types including transient, prolonged, and congenital hyperinsulinemic hypoglycemia. Congenital hyperinsulinemia is often due to genetic defects affecting insulin secretion and can lead to permanent brain injury if not treated aggressively. Initial treatment involves maintaining blood glucose levels through increased carbohydrate intake and intravenous glucose. Medications like diazoxide and octreotide aim to reduce insulin secretion. For resistant cases, genetic testing and imaging can help determine if surgery is required to remove part of the pancreas producing excess insulin. Early diagnosis and management are important to prevent hypoglycemia-induced brain damage in newborns.
Transient Neonatal Hypoglycemia, Revisited discusses glucose homeostasis in neonates and the types and management of neonatal hypoglycemia. After birth, neonates undergo a physiological transition as they adapt to intermittent feeding from transplacental glucose supply. This involves endocrine changes and the activation of pathways like glycogenolysis and gluconeogenesis to maintain blood glucose levels. Insulin secretion in neonates is not suppressed until very low glucose levels due to a lower threshold for insulin release that helps support growth in fetal life. Exposure to hypoxia after birth can prolong this fetal pattern of insulin secretion. Careful management is needed to avoid overtreatment of transitional hypoglycemia while preventing brain injury from severe hypoglycemia.
This document discusses neonatal hypoglycemia and glucose homeostasis in newborns. It begins by outlining glucose regulation in fetal life and the physiological transition that occurs after birth as the newborn adapts from receiving continuous glucose from the placenta to intermittent feeding. This transition involves endocrine changes including a fall in insulin and a rise in stress hormones that stimulate gluconeogenesis and glycogenolysis. The document then discusses the lower glucose threshold for insulin secretion in newborns compared to older infants, which can lead to transient hypoglycemia. It reviews studies showing normal glucose and ketone levels over the first days of life and defines thresholds for hypoglycemia.
The document discusses the management of neonatal hypoglycemia. It defines hypoglycemia and lists its common causes such as excess insulin, limited glycogen storage, and decreased gluconeogenesis. It classifies hypoglycemia as transient or persistent and describes the management and treatment approaches for each type. Nursing management plays an important role in prevention, maintaining normal blood glucose levels, and treating hypoglycemic events. Untreated hypoglycemia can lead to serious complications affecting the brain and heart.
Hypoglycaemia Biochemistry decrease in Glucose mechanismMirzaNaadir
油
glucose decrease due to lots of reason because there are lots of problem regerding it i detail i have given its problems and causes and symptoms and treatment also
Neonatal Hypoglycemia approach and Management .pptxAzad Haleem
油
Dr. Azad Haleem provides an overview of neonatal hypoglycemia. Key points include:
1) Neonates are susceptible to hypoglycemia due to their high brain glucose needs and immature defenses against low blood sugar. Transitional hypoglycemia is common in the first 48 hours while persistent low blood sugar beyond 48 hours requires investigation.
2) Causes of persistent hypoglycemia include hyperinsulinism, hypopituitarism, inborn errors of metabolism, and rarely other conditions. Diagnostic testing aims to identify the underlying etiology.
3) Management involves glucose supplementation, identifying and treating the cause, and careful feeding advancement. Specific treatments depend on the condition, such as diet modifications for
This document discusses neonatal hypoglycemia, including its definition, causes, signs and symptoms, and treatment. It defines neonatal hypoglycemia as a plasma glucose level below 40 mg/dL. Causes include increased glucose utilization, decreased substrate availability, or both. Signs are non-specific and include jitteriness, apnea, and seizures. Treatment involves oral feeds, IV dextrose if needed, and medications like hydrocortisone or diazoxide for persistent hypoglycemia. Close monitoring of at-risk infants is important to prevent neurological damage from prolonged hypoglycemia.
1) Hypoglycemia is common in newborns, affecting 1-3 per 1000 live births, with risk decreasing with increasing gestational age.
2) Significant neurodevelopmental deficits can occur in neonates who experience prolonged hypoglycemia. Studies in monkeys and infants show neuronal injury, particularly in parieto-occipital cortex and other regions.
3) There is no consensus on the definition and threshold for treating hypoglycemia. Guidelines generally recommend treating if blood glucose is less than 50 mg/dL in symptomatic newborns or less than 36 mg/dL in at-risk but asymptomatic newborns.
This document provides information on neonatal hyperbilirubinemia or jaundice. It defines jaundice and discusses the mechanisms and risk factors for both physiologic and pathologic hyperbilirubinemia in newborns. It outlines the evaluation, management, and treatment of hyperbilirubinemia including phototherapy and exchange transfusion. The major points covered are the definition of jaundice, causes of increased and decreased bilirubin levels in newborns, clinical assessment and lab evaluation of hyperbilirubinemia, guidelines for phototherapy and exchange transfusion, and methods to optimize phototherapy treatment.
This document discusses neonatal jaundice and hyperbilirubinemia. It begins by defining jaundice and hyperbilirubinemia. It then describes the metabolism of bilirubin, including transport to the liver, hepatic uptake, conjugation in the liver, and excretion in bile and stool. Causes of increased bilirubin production are discussed, including increased red blood cell production or breakdown. The document also discusses approaches to evaluating and managing neonatal jaundice and hyperbilirubinemia, including assessing risk factors, monitoring bilirubin levels, and guidelines for initiating phototherapy.
Blind Spots in AI and Formulation Science Knowledge Pyramid (Updated Perspect...Ajaz Hussain
油
This presentation delves into the systemic blind spots within pharmaceutical science and regulatory systems, emphasizing the significance of "inactive ingredients" and their influence on therapeutic equivalence. These blind spots, indicative of normalized systemic failures, go beyond mere chance occurrences and are ingrained deeply enough to compromise decision-making processes and erode trust.
Historical instances like the 1938 FD&C Act and the Generic Drug Scandals underscore how crisis-triggered reforms often fail to address the fundamental issues, perpetuating inefficiencies and hazards.
The narrative advocates a shift from reactive crisis management to proactive, adaptable systems prioritizing continuous enhancement. Key hurdles involve challenging outdated assumptions regarding bioavailability, inadequately funded research ventures, and the impact of vague language in regulatory frameworks.
The rise of large language models (LLMs) presents promising solutions, albeit with accompanying risks necessitating thorough validation and seamless integration.
Tackling these blind spots demands a holistic approach, embracing adaptive learning and a steadfast commitment to self-improvement. By nurturing curiosity, refining regulatory terminology, and judiciously harnessing new technologies, the pharmaceutical sector can progress towards better public health service delivery and ensure the safety, efficacy, and real-world impact of drug products.
Blind spots in AI and Formulation Science, IFPAC 2025.pdfAjaz Hussain
油
The intersection of AI and pharmaceutical formulation science highlights significant blind spotssystemic gaps in pharmaceutical development, regulatory oversight, quality assurance, and the ethical use of AIthat could jeopardize patient safety and undermine public trust. To move forward effectively, we must address these normalized blind spots, which may arise from outdated assumptions, errors, gaps in previous knowledge, and biases in language or regulatory inertia. This is essential to ensure that AI and formulation science are developed as tools for patient-centered and ethical healthcare.
Useful environment methods in Odoo 18 - Odoo 際際滷sCeline George
油
In this slide well discuss on the useful environment methods in Odoo 18. In Odoo 18, environment methods play a crucial role in simplifying model interactions and enhancing data processing within the ORM framework.
How to Configure Flexible Working Schedule in Odoo 18 EmployeeCeline George
油
In this slide, well discuss on how to configure flexible working schedule in Odoo 18 Employee module. In Odoo 18, the Employee module offers powerful tools to configure and manage flexible working schedules tailored to your organization's needs.
SOCIAL CHANGE(a change in the institutional and normative structure of societ...DrNidhiAgarwal
油
This PPT is showing the effect of social changes in human life and it is very understandable to the students with easy language.in this contents are Itroduction, definition,Factors affecting social changes ,Main technological factors, Social change and stress , what is eustress and how social changes give impact of the human's life.
How to Setup WhatsApp in Odoo 17 - Odoo 際際滷sCeline George
油
Integrate WhatsApp into Odoo using the WhatsApp Business API or third-party modules to enhance communication. This integration enables automated messaging and customer interaction management within Odoo 17.
Computer Application in Business (commerce)Sudar Sudar
油
The main objectives
1. To introduce the concept of computer and its various parts. 2. To explain the concept of data base management system and Management information system.
3. To provide insight about networking and basics of internet
Recall various terms of computer and its part
Understand the meaning of software, operating system, programming language and its features
Comparing Data Vs Information and its management system Understanding about various concepts of management information system
Explain about networking and elements based on internet
1. Recall the various concepts relating to computer and its various parts
2 Understand the meaning of softwares, operating system etc
3 Understanding the meaning and utility of database management system
4 Evaluate the various aspects of management information system
5 Generating more ideas regarding the use of internet for business purpose
APM event hosted by the South Wales and West of England Network (SWWE Network)
Speaker: Aalok Sonawala
The SWWE Regional Network were very pleased to welcome Aalok Sonawala, Head of PMO, National Programmes, Rider Levett Bucknall on 26 February, to BAWA for our first face to face event of 2025. Aalok is a member of APMs Thames Valley Regional Network and also speaks to members of APMs PMO Interest Network, which aims to facilitate collaboration and learning, offer unbiased advice and guidance.
Tonight, Aalok planned to discuss the importance of a PMO within project-based organisations, the different types of PMO and their key elements, PMO governance and centres of excellence.
PMOs within an organisation can be centralised, hub and spoke with a central PMO with satellite PMOs globally, or embedded within projects. The appropriate structure will be determined by the specific business needs of the organisation. The PMO sits above PM delivery and the supply chain delivery teams.
For further information about the event please click here.
Finals of Rass MELAI : a Music, Entertainment, Literature, Arts and Internet Culture Quiz organized by Conquiztadors, the Quiz society of Sri Venkateswara College under their annual quizzing fest El Dorado 2025.
Research & Research Methods: Basic Concepts and Types.pptxDr. Sarita Anand
油
This ppt has been made for the students pursuing PG in social science and humanities like M.Ed., M.A. (Education), Ph.D. Scholars. It will be also beneficial for the teachers and other faculty members interested in research and teaching research concepts.
QuickBooks Desktop to QuickBooks Online How to Make the MoveTechSoup
油
If you use QuickBooks Desktop and are stressing about moving to QuickBooks Online, in this webinar, get your questions answered and learn tips and tricks to make the process easier for you.
Key Questions:
* When is the best time to make the shift to QuickBooks Online?
* Will my current version of QuickBooks Desktop stop working?
* I have a really old version of QuickBooks. What should I do?
* I run my payroll in QuickBooks Desktop now. How is that affected?
*Does it bring over all my historical data? Are there things that don't come over?
* What are the main differences between QuickBooks Desktop and QuickBooks Online?
* And more
Prelims of Rass MELAI : a Music, Entertainment, Literature, Arts and Internet Culture Quiz organized by Conquiztadors, the Quiz society of Sri Venkateswara College under their annual quizzing fest El Dorado 2025.
Digital Tools with AI for e-Content Development.pptxDr. Sarita Anand
油
This ppt is useful for not only for B.Ed., M.Ed., M.A. (Education) or any other PG level students or Ph.D. scholars but also for the school, college and university teachers who are interested to prepare an e-content with AI for their students and others.
How to attach file using upload button Odoo 18Celine George
油
In this slide, well discuss on how to attach file using upload button Odoo 18. Odoo features a dedicated model, 'ir.attachments,' designed for storing attachments submitted by end users. We can see the process of utilizing the 'ir.attachments' model to enable file uploads through web forms in this slide.
5. THE BRAIN OF INFANT GROWS
MOST RAPIDLY IN 1ST YEAR OF LIFE
AND IT USES GLUCOSE AT RATE OF 4-6
MG/KG/MIN WHICH IS EQUAL TO ALL
THE ENDOGENOUS PRODUCTION.
6. Glucose is also a source of
membrane lipids,
Protein synthesis
provides structural proteins and
myelination imp for normal brain
maturation.
7. Persistent Hypoglycemia
Cerebral structural substrates are degraded
Energy usable intermediates :
lactate,pyruvate,amino acids,ketoacids
Supports brain metabolism,at the expense of
bain growth.
10. MANIFESTATION OF HYPOGLYCEMIA
IN CHILDHOOD
1. Feature associated with activation of autonomic nervous system and epinephrine release
Anxiety
Perspiration
Palpitation (tachycardia)
Pallor
Tremulousness
Weakness
Hunger
Nausea
Emesis
11. 2.Features associated with cerebral Glucopenia
Headache
Mental confusion
Visual disturbances ( acuity, diplopia)
Organic personality changes
Inability to concentrate
Dysarthria
Staring
Paresthesias
Dizziness
Amnesia
Ataxia, incoordination
Refusal to feed
Somnolence, lethargy
Seizures
Coma
12. ETIOLOGY
1..Decreased glucose production.
Prematurity
IUGR,
small for gestational age
Inadequate feed or caloric intake
2..Increase utilzation of glucose/hyperinsulinism
IDM
Beckwith wiedmann syndrome
Insulin producing tumor(nesidroblastosis)
14. CASE:
A 1300 gram male baby is born via normal spontaneous vaignal delivery
at 30 weeks gestation..mother is 29 years old with history of incompetent
cervix. At delivery, the infant has a weak cry.not taking feed.and is pale
and lethargic. His blood glucose is 30mg/dl.then he developed a seizure
15. Hypoglycaemia in premature baby is common due to lack of
Glycogen stores ,Decrease enzymatic activity (normaly decrease
Glycogen synthase activity and rate limiting enzyme for
gluconeogenesis phosphoenolpyruvate carboxykinase rise after
birth)
Inadequate substrates.
Decrease muscle protein,body fat
Decrease autonomic response
16. CASE:
A newborn present witt jitteriness.his weight is 4kg Physical
examination show a large plethoric infant who is tremulous. A murmer is
heard blood sugar is low.(35mg/dl)mother had gestational diabetes
during pregnancy
17. INFANT OF DIABETIC MOTHER (IDM)
Pathophysiology.
Maternal hypoglycemia cause fetal hyperglycemia and fetal pancreatic
response lead to fetal hyperinsulinemia
Fetal hyper insulinemia and hyperglycemia cause increase hepatic uptake
of glucose... Accelerated lipogenesis and augmented protein synthesis so
when separations of placenta at birth sudden interrupted glucose infusion
without a proportional effect on hyperinsulinisn result in hypoglycemia
19. PERSISTENCE OR RECURRENT
HYPOGLYCEMIA IN INFANT AND
CHILDREN
Hyperinsulinism is the most common cause of persistent
hypoglycemia in early infancy.
Infants who have hyperinsulinism may be macrosomic at birth,
reflecting the anabolic effects of insulin in utero.
There is no history or biochemical evidence of maternal diabetes.
Factitious Hypoglycemia
Hypoglycemia from exogenous administration of insulin as a form of
child abuse.
23. measurement of serum IGFBP-1 concentration may help
diagnose hyperinsulinism. The secretion of IGFBP-1 is
acutely inhibited by insulin action;
IGFBP-1 concentrations are low during hyperinsulinism-
induced hypoglycemia.
The differential diagnosis of endogenous hyperinsulinism
includes Diffuse 硫-cell hyperplasia or focal 硫-cell
microadenoma .
The distinction between these 2 major entities is important
because the diffuse hyperplasia, if unresponsive to medical
therapy, requires near-total pancreatectomy
25. ISLET CELL ADENOMA
Hyperinsulinemia as a result of islet cell adenoma should be
considered in anychild 5 yr who presents with hypoglycemia.
Islet cell adenomas do not lightup during scanning with 18 F-
labeled L -dopa. An islet cell adenoma in a child should arouse
suspicion of the possibility of multiple endocrine neoplasia
typeI (Wermer syndrome), which involves mutations in the
menin gene and may be associated with hyperparathyroidism
and pituitary tumors
Islet cell adenomas at this age are treated by surgical excision.
27. CASE:
A 36 week gestation infant was delivered
weighing 3.9kg.He had an OMPHALOCELE and
large tongue .there was no other abnormality
observed. On laboratory investigations, there
was hypoglycaemia.
30. CASE:
A 6 year old child present with tiredness and weight loss for few
weeks.There is blackening of skin colour due to generalised
pigmentation.on laboratory investigations. Na is
118(hyponatremia),k 7.5(hyperkalemia) ..and hypoglycaemia.
ACTH and renin level are raised
31. ADDISON'S DISEASE
Acquired primary adrenal insufficiency originating in the gland
itself..term addison disease..
Congenital adrenal hyperplasia
Infection..
TB adrenalitis
meningococcal sepsis or waterhouse friederichsen syndrome.
Secondary cause
Hypothalamic or pituitary tumor
Due to Cortisol deficiency. Hypoglycemia that may associated with
ketosis as body attempts to utilise fatty acid as alternative energy source
32. Case:
A 9 month old boy present with sweating and tachypnea.on
clincal examination, there is 5cm hepatomegaly.RBS is
40mg/dl.liver biopsy confirm Glycogen storage disease
Type I Glucose-6-Phosphatase Deficiency
Type III Glycogen Storage Disease(debrancher enzyme
deficiancy)
Liver Phosphorylase Deficiency (Type VI Glycogen Storage
disease)
33. Diagnosis is made by simple investigation
Blood gases thats show
acidosis..
Hypoglycaemia
Hyperuricemia
Hyperlipidiemia
G6PD is treated with a special diet in order to maintain normal
glucose levels, prevent hypoglycemia and maximize growth and
development. Frequent small servings of carbohydrates must be
maintained during the day and night throughout the life. Calcium,
vitamin D and iron supplements maybe recommended to avoid
deficits.Uncooked corn starch.that are comlex carbs...are used
34. CASE:
A 6 day old baby present with poor feeding and vomiting....LFT
show hyperbillirubinemia..there is hypoglycaemia.
Opthalmoloscopic examination central cataract .blood cultures
are positive for E.Coli.he does well on intravenous fluids. when
began on routine infant formula his symptoms return.
35. GLACTOCEMIA
It is due to galactose 1 phosphate uridyl transferase deficiency..
Urine for reducing substance is positive..urine for ketone positive..direct
enzyme activity in RBC is gold standard..
Management..avoiding all milk and milk containg products..and lactose
free formula
36. CASE
A 9 years old boy present with jaundice for last 10 days..now he has
impaired consciousness. He has fever and vomiting. On examination,
there is ascites and he is in coma.on investigation. There is
hypoglycaemia and LFT are raised
38. Frequent bedside monitoring of blood glucose every 2-4 hours.
Severe hypoglycaemia is develop in majority of children..that lead
to CNS impairments..so iv administration of glucose is required to
prevent hypoglycaemia So prevention and management of
hypoglycemia is important
40. Acute Presentation of symptoms:
1. Obtain blood sample before and 30 min after glucagon
administration.
2. Obtain urine as soon as possible. Examine for ketones; if not
present and hypoglycemia confirmed, suspect hyperinsulinemia or
fatty acid oxidation defect; if present, suspect ketotic, hormone
deficiency, inborn error of glycogen metabolism, or defective
gluconeogenesis.
3. If glycemic increment after glucagon exceeds 40 mg/dL above
basal,suspect hyperinsulinemia.
4. If insulin level at time of confirmed hypoglycemia is >5 袖U/mL,
suspect endogenous hyperinsulinemia; if >100 袖U/mL, suspect
factitious hyperinsulinemia (exogenous insulin injection). Admit to
hospital for supervised fast.
5.If cortisol is <10 袖g/dL or growth hormone is <5 ng/mL, or both,
suspect adrenal insufficiency or pituitary disease, or both. Admit to
hospital forhormonal testing and neuroimaging.
42. Note:
unusual behavior of any sick newborn should prompt a
bedside glucose determination .
However, because glucose meters have an accuracy of only
賊20%, any blood glucose value <60 mg/dL must be confirmed
by a formal laboratory measurement that is performed
without delay on a blood sample preserved in a tube that
prevents glycolysis, which can cause spurious low values.